Preliminary results from the recent CATALYST study found hypercortisolism in 24% of patients with type 2 diabetes who are screened for the condition. Given the high prevalence of hidden hypercortisolism among patients with type 2 diabetes, early identification and treatment...

In this video-based program, a multispecialty expert panel provides perspectives on the diagnosis and treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and its progressive subtype, metabolic dysfunction–associated steatohepatitis (MASH), which pose a critical and escalating public health crisis, particularly...

Recent findings indicate that hypercortisolism can be an underlying contributor to difficult-to-control type 2 diabetes (T2D), and it may occur with lower cortisol levels than noted in overt Cushing syndrome. In this program, expert faculty discuss new perspectives on the...

Congenital adrenal hyperplasia (CAH) is a group of rare autosomal recessive disorders that arise from genetic mutation affecting enzymes involved in cortisol synthesis. Depending on the severity of mutations and the loss of functionality of 21-hydroxylase, CAH can take 2...

A variety of continuous glucose monitoring (CGM) devices are available to provide ongoing data and help patients with diabetes and their clinicians achieve improved glucose control and reduce the risk of complications (eg, hypoglycemia). In this Burst CME program, an...

This video-based program is designed to provide education on identifying hypercortisolism using a unique format in which the potential consequences of a delayed diagnosis will be revealed using patient-clinician interaction videos. The faculty will focus on recognizing subclinical or atypical...

The BURST CME™ format is an online, on-demand video program designed to deliver concise, modular education. In these modules, Hanford Yau, MD, and Stephen J. Greene, MD, review the relationship between hypercortisolism and hypertension, identifying patients with resistant hypertension who...

With the expanding role of continuous glucose monitoring (CGM) devices in diabetes management, clinicians must stay abreast of the available US FDA-approved devices, latest guideline recommendations, general counseling strategies, and how they are already being or may be integrated with...

The pathogenesis of type 1 diabetes (T1D) is now recognized to involve a progression of disease that advances through distinct stages prior to the onset of symptoms. With therapy now available to delay the onset of symptomatic T1D—and give the...

This Burst CME features an expert-led video discussion on TL1A pathophysiology, which has led to a promising new class of biologics for moderate-to-severe IBD with potential to transform care by addressing both inflammatory and fibrostenotic complications. Emerging evidence on TL1A...